Presentation ESC 2025 Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk Presenter: Brian Bergmark August 30, 2025 REGISTER for free or LOG IN to view this content Clinical Cardiology Clinical Pharma Lipids Presentation ESC 2025 Up Next Presentation ESC 2025 Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes: The DUAL-ACS Trial Presenter: David Newby September 03, 2025 More slides + Presentation ESC 2025 Dual or single antiplatelet therapy after coronary artery bypass grafting in patients with acute coronary syndrome: The TACSI trial Presenter: Anders Jeppsson September 01, 2025 Presentation ESC 2025 BETAMI-DANBLOCK: Randomized Discontinuation of Beta-blockers After Myocardial Infarction in Patients Without Heart Failure Presenter: Eva Prescott August 30, 2025 We Recommend
Presentation ESC 2025 Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes: The DUAL-ACS Trial Presenter: David Newby September 03, 2025
Presentation ESC 2025 Dual or single antiplatelet therapy after coronary artery bypass grafting in patients with acute coronary syndrome: The TACSI trial Presenter: Anders Jeppsson September 01, 2025
Presentation ESC 2025 BETAMI-DANBLOCK: Randomized Discontinuation of Beta-blockers After Myocardial Infarction in Patients Without Heart Failure Presenter: Eva Prescott August 30, 2025